Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
-
COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
-
SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
-
COMMENTARY／JSHP to Promote Use of Generics
June 8, 2009
-
COMMENTARY／Combination Drugs Becoming a "Boom"
June 1, 2009
-
COMMENTARY／Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
-
COMMENTARY／Why Does the Use of Generics Not Increase?
April 27, 2009
-
EMTs Allowed to Administer Epipen
April 27, 2009
-
COMMENTARY／Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
-
The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
-
COMMENTARY／Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
-
Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
-
COMMENTARY／Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
-
COMMENTARY／National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
-
Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
-
Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
-
Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
-
COMMENTARY／Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
-
COMMENTARY／Aiming at Further Growth beyond Global Recession
January 12, 2009
-
COMMENTARY／Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…